Trial Profile

Effects of Dopaminergic Therapy in Patients With Alzheimer's Disease: a Phase II 24-week, Randomized, Double-blind Placebo Controlled Study

Status: Completed

Phase of Trial: Phase II

Latest Information Update: 17 Jul 2020

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Rotigotine (Primary)
Indications Alzheimer's disease
Focus Therapeutic Use
Acronyms DOPAD

Most Recent Events

15 Jul 2020 Results published in the Media Release
15 Jul 2020 According to Alzheimers Drug Discovery Foundation media release, data from this trial was published in JAMA Network Open. Study is Funded by the Alzheimer's Drug Discovery Foundation.
14 Dec 2018 Status changed to completed.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com